Market Overview

Second Sight Appoints Pat Ryan Chief Operating Officer

Share:

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or
"the Company"), a developer, manufacturer and marketer of implantable
visual prosthetics that are intended to create an artificial form of
useful vision to blind patients, announced today that Pat Ryan has been
appointed Chief Operating Officer, effective immediately. In this newly
created role, Mr. Ryan will assume responsibility for Research &
Development, Manufacturing, Planning & Materials, Quality Assurance, and
Information Technology. He will report to Will McGuire, Second Sight's
President and Chief Executive Officer.

"Pat brings a wealth of knowledge from both large and small medical
device firms, and we are delighted to welcome him to the Second Sight
team. He has successfully led organizations in multiple regions of the
world including COO roles at several public medical device companies.
Pat's deep knowledge in manufacturing, quality assurance and R&D will be
especially critical as Second Sight continues to develop the Orion™
Cortical Visual Prosthesis System (Orion) and prepares for significantly
higher manufacturing volumes in future years," said McGuire.

"Pat has the perfect background to ready Second Sight for an exciting
future with Orion. His strong leadership in key areas will be
invaluable, as we move the Orion clinical and development programs
forward and prepare for success in a market that includes hundreds of
thousands of potential patients worldwide," said Gregg Williams,
Chairman of the Board.

Mr. Ryan's previous roles include serving as Chief Operations Officer at
Synaptive Medical, and Chief Operating Officer at Lucerno Dynamics and
Insulet Corporation. He also served as Chief Operating Officer and
President, International, at Alphatec Spine. Earlier in Mr. Ryan's
career, he held multiple leadership positions at Guidant and Abbott
Vascular, including Divisional Vice President of Worldwide Operations at
Abbott Vascular as well as Vice President & Managing Director for
Guidant's manufacturing facility in Ireland. Following his graduation
from the United States Naval Academy with a Bachelor of Science degree
in Economics, Mr. Ryan served as an officer in the U.S. Navy. He then
received a Master of Science degree in Petroleum Management from the
University of Kansas.

The Company recently completed enrollment of the first five subjects,
ahead of schedule, with Orion at the Ronald Reagan UCLA Medical Center
(UCLA) and the Baylor College of Medicine in Houston (Baylor) as part of
Second Sight's early feasibility clinical study. All five subjects have
had their Orion systems activated, and all subjects reported seeing
light from virtually all electrodes and stimulation parameters are
within expected ranges. As a result of these successes, the Company is
now progressing with more complex testing involving real-time video
input. Over the coming months, Second Sight intends to collect
additional important clinical and performance data to support the safety
and efficacy of this breakthrough device.

"I am thrilled to join Second Sight at this exciting time and to help
the organization build on its significant achievements to date. I look
forward to working with Will and the rest of the team to scale the
infrastructure and team necessary for the commercial success of Orion,
and to enhance shareholder value," said Pat Ryan, Chief Operating
Officer.

About Second Sight

Second Sight Medical Products, Inc. (NASDAQ:EYES) develops, manufactures
and markets implantable visual prosthetics that are intended to deliver
useful artificial vision to blind individuals. A recognized global
leader in neuromodulation devices for blindness, the company is
committed to developing new technologies to treat the broadest
population of sight-impaired individuals.

Second Sight's Argus® II Retinal Prosthesis System is the
only FDA and CE Mark approved device for treating retinitis pigmentosa,
with proven implant durability of multiple years. In 2016, the company
published five year results. Today, several Argus II devices have been
implanted and operational in humans for more than 10 years. The company
is developing the Orion™ I Visual Cortical Prosthesis which is intended
to provide useful artificial vision to individuals who are blind due to
various causes. The company's U.S. headquarters are in Los Angeles, and
European headquarters are in Lausanne, Switzerland. More information is
available at www.secondsight.com.

About Retinitis Pigmentosa

Affecting one in 4,000 individuals worldwide, retinitis pigmentosa (RP)
is a rare, inherited genetic disorder that damages retinal cells called
photoreceptors. Photoreceptors absorb and convert light into electrical
signals sent to other retinal cells, then through the optic nerve to the
brain which processes them into images. Common early symptoms of RP,
often experienced in childhood, include difficulty seeing at night and
lost peripheral vision. Later, the disease may lead to blurring of
vision, tunnel vision, loss of central vision or loss of the ability to
see colors. In many cases, severe vision problems occur in early
adulthood. RP may impact an individual's ability to perform essential
tasks of daily living such as reading, driving, walking without
assistance, or recognizing faces and objects.

About the Argus II Retinal Prosthesis System

The Argus® II Retinal Prosthesis System is an established,
FDA and CE mark approved retinal implant that delivers a useful form of
artificial vision to individuals who are blind due to severe to profound
retinitis pigmentosa (RP). The Argus II works in place of lost
photoreceptor cells and sends electrical pulses to remaining viable
retinal cells to induce visual perception. The system works by
converting images captured by a miniature video camera mounted on
glasses into a series of small electrical pulses, which are transmitted
wirelessly to an array of electrodes implanted on the surface of the
retina. These pulses stimulate the retina's remaining cells, enabling
perception of patterns of light in the brain. The user learns to
interpret these visual patterns in order to regain some visual function.
The Argus platform, which leverages the unique, patented design of its
60-contact array, is supported by more than 10 years of clinical
experience and has been evaluated in multiple peer reviewed
publications. Argus II was also the first retinal neuromodulation
prosthesis to receive widespread commercial approval and is presently
available at more than 50 leading medical centers in North America,
Europe, the Middle East and Asia. Further information on the long-term
benefits and risks can be found in the peer reviewed paper at: http://www.sciencedirect.com/science/article/pii/S0161642016305796.

About the Orion Visual Cortical Prosthesis System

Leveraging Second Sight's 20 years of experience in neuromodulation for
vision, the Orion™ Visual Cortical Prosthesis System is an implanted
cortical stimulation device intended to provide useful artificial vision
to individuals who are blind due to a wide range of causes, including
glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms
of cancer and trauma. The Orion System is intended to convert images
captured by a miniature video camera mounted on glasses into a series of
small electrical pulses. The device is designed to bypass diseased or
injured eye anatomy and to transmit these electrical pulses wirelessly
to an array of electrodes implanted on the surface of the brain's visual
cortex, where it is intended to provide the perception of patterns of
light. A feasibility study of the Orion I device is currently underway
at the Ronald Reagan UCLA Medical Center in Los Angeles and Baylor
College of Medicine in Houston. No published in-human data is available
yet for the Orion system. Based on the results of this first in-human
testing of the Orion I cortical stimulation device, the company
anticipates initiation of the next study in 2019.

Forward looking statement

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange and Exchange Act of 1934, as
amended, which are intended to be covered by the "safe harbor" created
by those sections. All statements in this release that are not based on
historical fact are "forward looking statements." These statements may
be identified by words such as "estimates," "anticipates," "projects,"
"plans," "goal," or "planned," "seeks," "may," "will," "expects,"
"intends," "believes," "should," and similar expressions, or the
negative versions thereof, and which also may be identified by their
context. All statements that address operating performance or events or
developments that Second Sight expects or anticipates will occur in the
future, such as stated objectives or goals, or that are not otherwise
historical facts, are forward-looking statements. While management has
based any forward-looking statements included in this release on its
current expectations, the information on which such expectations were
based may change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from
those in the forward-looking statements as a result of various factors,
including those risks and uncertainties described in the Risk Factors
and in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our Annual Report, on Form 10-K, filed
on March 20, 2018, our most recent 10-Q, filed on August 7, 2018, and
our other reports filed from time to time with the Securities and
Exchange Commission. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution
readers not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as otherwise
required by the federal securities laws, we disclaim any obligation or
undertaking to publicly release any updates or revisions to any
forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto, or any change in events,
conditions, or circumstances on which any such statement is based.

View Comments and Join the Discussion!